Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 10CNS 4Breast 3Sarcoma 1Other solid neoplasm 1Myeloid 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Oropharyngeal Neoplasms 1Mouth Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Head and Neck Neoplasms 1Carcinoma 1

Interventions

pembrolizumab 183Cisplatin 158Radiotherapy 77Carboplatin 71Radiotherapy, Intensity-Modulated 70Cetuximab 68Magnetic Resonance Spectroscopy 65Nivolumab 64Paclitaxel 52Docetaxel 50Specimen Handling 45Radiation 34Gemcitabine 33Fluorouracil 31Surveys and Questionnaires 28Biopsy 27Drug Therapy 26toripalimab 25Platinum 25Surgical Procedures, Operative 24Standard of Care 231,2-diaminocyclohexaneplatinum II citrate 23cemiplimab 22Capecitabine 21atezolizumab 20Chemoradiotherapy 20Ipilimumab 19tislelizumab 18durvalumab 18Taxes 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Celecoxib × Head & Neck × 1 year × Clear all
NCT06997068 2026-05-11

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population

Mayo Clinic

Phase 2 Recruiting
25 enrolled
Head & Neck

Carcinoma, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡